Summit Therapeutics PLC Sponsored ADR Stock

$29.30

18.77% today

Nasdaq, May 02, 04:49 pm CET

ISIN

US86627R1023

Symbol

SMMT

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Summit Therapeutics PLC Sponsored ADR Stock price

$24.67

+21.37 647.58% 5Y

Nasdaq, Closing price Thu, May 01 2025

+0.55 2.28%

ISIN

US86627R1023

Symbol

SMMT

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$18.20b
Enterprise Value	$17.79b
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
P/B ratio (TTM) P/B ratio	46.81
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-211.29m
Free Cash Flow (TTM) Free Cash Flow	$-142.66m
Cash position	$412.67m
EPS (TTM) EPS	$-0.31
P/E forward	negative
Short interest	21.08%

As a Free StocksGuide user, you can view scores for all 6,792 stocks worldwide.

Get Started for Free Today

Summit Therapeutics PLC Sponsored ADR Stock Analysis

Unlock Scores for Free

??

9 Analysts have issued a Summit Therapeutics PLC Sponsored ADR forecast:

9x Buy

100%

More details on Analyst Estimates Including Price Targets

9 Analysts have issued a Summit Therapeutics PLC Sponsored ADR forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Summit Therapeutics PLC Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	- -	- 100%
- Direct Costs	0.09 0.09	96% 96% -
Gross Profit	-0.09 -0.09	96% 96% -
- Selling and Administrative Expenses	60 60	130% 130% -
- Research and Development Expense	151 151	154% 154% -
EBITDA	-211 -211	141% 141% -
- Depreciation and Amortization	0.09 0.09	96% 96% -
EBIT (Operating Income) EBIT	-211 -211	135% 135% -
Net Profit	-221 -221	64% 64% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Summit Therapeutics PLC Sponsored ADR Stock News

Positive

The Motley Fool

●

about 3 hours ago

This Soaring Stock Just Delivered More Good News. Time to Buy?

It's hard to find a biotech company that has performed better than Summit Therapeutics (SMMT 2.86%) in the past year. The stock is up by a whopping 512%, and it's no secret why.

Neutral

Business Wire

●

about 19 hours ago

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its operational progress for the first quarter ended March 31, 2025. Operational & Corporate Updates Operational progress continues with ivonescimab (SMT112), an investigational, potentially first-in-class bispecific antibody ...

Negative

The Motley Fool

●

7 days ago

Why Biotech Stars Summit Therapeutics and BioNTech Plunged, Even as This Chinese Rival Surged Today

Shares of biotech companies involved in the development of monoclonal antibody cancer therapies were moving all over the place on Friday. Both U.S.-based Summit Therapeutics (SMMT -36.19%) and BioNTech (BNTX -15.40%) were down significantly, plunging 36.1% and 15.4%, respectively, in Friday's trading.

More Summit Therapeutics PLC Sponsored ADR News

Company Profile

Summit Therapeutics Plc operates as a holding company, which engages in the discovery, development, and commercialization of antibiotic medicines. The company operates through the Drug Development segment, which covers its research and development activities carried out by the Group. Summit Therapeutics was founded by Stephen Graham Davies and Kay Dame Davies in January 2003 and is headquartered in Abingdon, the United Kingdom.

Head office	United Kingdom
CEO	Robert Zanganeh
Employees	159
Founded	2003
Website	www.smmttx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now